Last reviewed · How we verify
Membrane Bound Cytokine Modified TIL
GC203, a membrane-bound cytokine modified TIL developed by Shanghai Juncell Therapeutics, is in early clinical development for advanced gynecologic tumors. The drug leverages TIL technology to enhance immune response against cancer cells, showing promise in preclinical and early clinical studies.
At a glance
| Generic name | Membrane Bound Cytokine Modified TIL |
|---|---|
| Sponsor | Shanghai Juncell Therapeutics |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: